SEC Company Response from AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702) (FFR) — Jul 20, 2017
AIxCrypto Holdings, Inc. (AIXC) (CIK 0001460702)
Date: July 20, 2017 · CIK: 0001460702 · Accession: 0001493152-17-008018
AI Filing Summary & Sentiment
Reasoning
Letter
Ritter Pharmaceuticals, Inc.
1880 Century Park East, Suite 1000
Los Angeles, CA 90067
(310) 203-1000
July 20, 2017
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Chris Edwards and Suzanne Hayes
Re: Ritter Pharmaceuticals, Inc. – Request for Acceleration
Registration Statement on Form S-1
File No. 333- 219147
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333- 219147) (the “Registration Statement”), so that it may become effective at 5:00 p.m. Eastern Standard Time on July 20, 2017, or as soon thereafter as practicable. Under separate cover, you will receive a letter from the managing underwriter of the proposed offering joining in the Registrant’s request for acceleration of the effectiveness of the Registration Statement.
The Registrant hereby authorizes each of Wendy Grasso, Esq., Aron Izower, Esq. and Michael Sanders, Esq. of Reed Smith LLP, attorneys for the Registrant, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso at (212) 549-0216 or, in her absence, Mr. Izower at (212) 549-0393 or Mr. Sanders at (310) 734-5232.
RITTER PHARMACEUTICALS, INC.
By: /s/ Michael D. Step
Michael D. Step
Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
Ritter Pharmaceuticals, Inc.
1880 Century Park East, Suite 1000
Los Angeles, CA 90067
(310) 203-1000
July 20, 2017
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Chris Edwards and Suzanne Hayes
Re:
Ritter Pharmaceuticals, Inc. – Request for Acceleration
Registration Statement on Form S-1
File No. 333- 219147
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the
Securities Act of 1933, as amended, Ritter Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of
the effective date of its Registration Statement on Form S-1 (File No. 333- 219147) (the “Registration Statement”),
so that it may become effective at 5:00 p.m. Eastern Standard Time on July 20, 2017, or as soon thereafter as practicable.
Under separate cover, you will receive a letter from the managing underwriter of the proposed offering joining in the Registrant’s
request for acceleration of the effectiveness of the Registration Statement.
The Registrant hereby authorizes
each of Wendy Grasso, Esq., Aron Izower, Esq. and Michael Sanders, Esq. of Reed Smith LLP, attorneys for the Registrant, to orally
modify or withdraw this request for acceleration.
The Registrant requests
that it be notified of such effectiveness by a telephone call to Wendy Grasso at (212) 549-0216 or, in her absence, Mr. Izower
at (212) 549-0393 or Mr. Sanders at (310) 734-5232.
RITTER PHARMACEUTICALS, INC.
By:
/s/ Michael D. Step
Michael D. Step
Chief Executive Officer